全文获取类型
收费全文 | 622篇 |
免费 | 26篇 |
国内免费 | 2篇 |
学科分类
医药卫生 | 650篇 |
出版年
2024年 | 1篇 |
2023年 | 8篇 |
2022年 | 4篇 |
2021年 | 17篇 |
2020年 | 7篇 |
2019年 | 10篇 |
2018年 | 16篇 |
2017年 | 16篇 |
2016年 | 12篇 |
2015年 | 18篇 |
2014年 | 29篇 |
2013年 | 34篇 |
2012年 | 43篇 |
2011年 | 54篇 |
2010年 | 22篇 |
2009年 | 21篇 |
2008年 | 35篇 |
2007年 | 39篇 |
2006年 | 40篇 |
2005年 | 35篇 |
2004年 | 28篇 |
2003年 | 32篇 |
2002年 | 34篇 |
2001年 | 9篇 |
2000年 | 1篇 |
1999年 | 3篇 |
1998年 | 10篇 |
1997年 | 11篇 |
1996年 | 7篇 |
1995年 | 8篇 |
1994年 | 11篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1976年 | 1篇 |
1969年 | 1篇 |
1964年 | 1篇 |
1937年 | 1篇 |
1936年 | 1篇 |
排序方式: 共有650条查询结果,搜索用时 15 毫秒
41.
Tateyama M Saito N Fujihara K Shiga Y Takeda A Narikawa K Hasegawa T Taguchi Y Sakuma R Onodera Y Ohnuma A Tobita M Itoyama Y 《Internal medicine (Tokyo, Japan)》2003,42(10):1035-1038
Familial occurrence of inclusion body myositis is extremely rare, and only a few cases in Western countries have been reported. In these reports, a strong association of this disease with DR3 (DRB1*0301/0302) and the efficacy of immunosuppressants suggested that an immune pathomechanism is involved in the disease. We, for the first time, report two Japanese sisters who suffered myopathy clinicopathologically similar to inclusion body myositis. One sister received corticosteroid and azathioprine and the therapy relieved dysphagia. Both of our patients had DR15(2)/4 (DRB1*1502/0405), suggesting a distinct genetic association with the disease in the Japanese population. 相似文献
42.
43.
Iijima S Kikkawa N Kurokawa E Yamamoto H Kato T Tsujie M Ohshima S Hayashi T Naoi Y Hatanaka T Danno M Sakon M Nagano H Dono K Nakamori S Umeshita K Monden M 《Gan to kagaku ryoho. Cancer & chemotherapy》2003,30(11):1669-1672
The prognosis of advanced hepatocellular carcinoma (HCC) is extremely poor. Patient 1 was a 43-year-old male with major portal tumor thrombi. He received combination therapy consisting of continuous arterial infusion (MTX 30 mg/m2, day 1, CDDP/5-FU 6 mg/m2: 250 mg/m2, day 1-14) and subcutaneous injection of IFN-alpha (500 x 10(4) U, 3 times a week, 4 weeks). Patient 2 was a 66-year-old male with major hepatic venous tumor thrombi. He received combination therapy consisting of continuous arterial infusion (5-FU 6 mg/m2: 250 mg/m2, day 1-14) and subcutaneous injection of IFN-alpha (500 x 10(4) U, 3 times a week, 4 weeks). Decrease in tumor was observed in both patients markers and marked regression of tumor was observed in both patients. They are still in complete response. This combination therapy is an effective strategy for advanced HCC. 相似文献
44.
TS-1 and lentinan combination immunochemotherapy for advanced or recurrent gastric cancer: a preliminary report 总被引:3,自引:0,他引:3
Kimura Y Iijima S Kato T Tsujie M Naoi Y Hayashi T Tanigawa T Yamamoto H Kurokawa E Matsuura N Kikkawa N 《Gan to kagaku ryoho. Cancer & chemotherapy》2003,30(11):1791-1793
The immunocompetence and nutritional state of patients with advanced or recurrent gastric cancer is low, making it important to conduct chemotherapy while at the same time improving or maintaining their immunocompetence and nutritional state. To reduce the side effects but not the antitumor effect of TS-1, a 2-week regime of TS-1, and 1-week drug-free interval, in combination with the immunotherapeutic agent lentinan (LNT) was started in 5 patients with advanced or recurrent gastric cancer. Toxicity, efficacy, immunocompetence and nutritional state were investigated preliminarily to examine whether or not usefulness of lentinan could be evaluated. The IAP tended to decrease. TS-1 and lentinan combination immunochemotherapy was able to be carried out safely in patients with advanced recurrent gastric cancer. In order to examine the usefulness of combined LNT, it is thought to be necessary to perform a randomized trial using toxicity and not only efficacy but QOL and immunological and nutritional parameters as indicators. 相似文献
45.
Yutaka Kimura Nobuteru Kikkawa Shohei Iijima Takeshi Kato Yasuto Naoi Taro Hayashi Takahiko Tanigawa Hitoshi Yamamoto Eiji Kurokawa 《Gastric cancer》2003,6(1):34-39
Background
The response rate of advanced or recurrent gastric cancer to S-1 (TS-1®) is 46.5%, which is higher than the response rate of this type of cancer to any other anticancer agent. However, the incidence of adverse reactions to this drug has also been reported to be as high as 83.2%. According to a postmarketing survey, adverse reactions to this drug begin to appear 2–3 weeks after the start of drug administration. With these findings in mind, we recently devised a new dosing regimen for the drug, by which the drug is administered for 2-week periods separated by 1-week drug-free intervals (the 2-week regimen). The aim of this retrospective study was to evaluate the efficacy and feasibility of the 2-week regimen in comparison with a 4-week dosing regimen with a 2-week interval between sessions (the 4-week regimen) as the historical control.Methods
The subjects were 27 patients with advanced or recurrent gastric cancer who received S-1 therapy at our center between September 1999 and November 2001. Of these patients, 14 who received the 4-week regimen before January 2001 served as historical controls, and the results in these patients were compared with those of the remaining 13 patients, who received the 2-week regimen after February 2001. Patient backgrounds, adverse reactions, compliance, and efficacy were investigated retrospectively.Results
The incidence of adverse reactions tended to be lower in the 2-week-regimen group (77%) than in the 4-week-regimen group (93%). The percentage of patients who received the drug for 6 months in complete compliance with the dosing schedule, as calculated by the Kaplan-Meier method, was 85% in the 2-week-regimen group and 40% in the 4-week-regimen group. The response rate to the drug was 23% in the 2-week-regimen group and 21% in the 4-week-regimen group.Conclusion
These results suggest that this 2-week regimen may mitigate adverse reactions and prolong the medication period.46.
Yamada SM Hayashi Y Takahashi H Teramoto A Matsumoto K Yamada S 《Journal of neuro-oncology》2001,52(3):237-240
Gliomatosis cerebri is considered grade III astrocytoma because of the short survival period of patients with this tumor, while the tumor histologically consists of widespread low grade astrocytoma cells. The authors tried to clarify this discrepancy by applying genetic analysis of the tumor. A 29-year-old man originally presented with mild headache and showed diffuse high intensity areas in both hemispheres and in the cerebellum by T2-weighted magnetic resonance imaging (MRI) without gadolinium-dimeglumine (Gd)-enhancement in T1-weighted imaging. Histological diagnosis was gliomatosis cerebri with diffuse grade II astrocytoma. Seven months after temporary improvement following irradiation and chemotherapy, he developed progressive mental deterioration, and died in one year after the surgery. At this time T1-weighted imaging showed Gd-enhanced lesions with enlargement only of the cerebellar tumor. Genetic analysis demonstrated positive FGFR 1 and less FGFR 2 mRNA in the tumor tissue, and FGFR 1 mRNA was type dominant. These results indicated that the genetic features of this tumor are similar to those of glioblastoma multiforme concerning FGFR expression. The authors conclude that genetic investigation of the tumor tissue is required to predict the prognosis of gliomatosis cerebri patients, in addition to imaging and histological examinations. 相似文献
47.
Yasuto Yoneshima Satoshi Morita Masahiko Ando Satoru Miura Hiroshige Yoshioka Tetsuya Abe Terufumi Kato Masashi Kondo Yukio Hosomi Katsuyuki Hotta Nobuyuki Yamamoto Junji Kishimoto Yoichi Nakanishi Isamu Okamoto 《Clinical lung cancer》2017,18(1):100-103
Background
Nanoparticle albumin-bound (nab) paclitaxel is a promising new therapeutic agent for all histologic types of non–small-cell lung cancer (NSCLC). We recently performed a phase 2 study of weekly nab-paclitaxel in patients with previously treated advanced NSCLC, finding promising activity and acceptable toxicity for this regimen. We have now designed a randomized phase 3 intergroup study (J-AXEL, UMIN000017487) to examine the clinical benefit and safety of nab-paclitaxel compared to docetaxel in patients with previously treated advanced NSCLC.Patients and Methods
Patients are randomized to receive either docetaxel (60 mg/m2 on day 1 every 3 weeks, control arm) or nab-paclitaxel (100 mg/m2 on days 1, 8, and 15 every 3 weeks, experimental arm), with each drug being administered until disease progression or unacceptable toxicity. The study will evaluate the noninferiority of nab-paclitaxel relative to docetaxel for the primary end point of overall survival.Conclusion
If the primary objective is achieved, this study will provide evidence for a new alternative treatment option for patients with previously treated advanced NSCLC. 相似文献48.
Tanaka K Okada Y Kanno T Otomo A Yanagisawa Y Shouguchi-Miyata J Suga E Kohiki E Onoe K Osuga H Aoki M Hadano S Itoyama Y Ikeda JE 《Experimental neurology》2008,211(2):378-386
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by a selective loss of motor neurons in the motor cortex, brainstem, and spinal cord. It has been shown that oxidative stress plays a pivotal role in the progression of this motor neuron loss. We have previously reported that L-745,870, a dopamine D4 receptor antagonist, selectively inhibits oxidative stress-induced cell death in vitro and exerts a potent neuroprotective effect against ischemia-induced neural cell damage in gerbil. To investigate the efficacy of L-745,870 in the treatment of ALS, we here conducted a chronic administration of L-745,870 to transgenic mice expressing a mutated form of human superoxide dismutase gene (SOD1H46R); a mouse model of familial ALS, and assessed whether the mice benefit from this treatment. The pre-onset administration of L-745,870 significantly delayed the onset of motor deficits, slowed the disease progression, and extended a life span in transgenic mice. These animals showed a delayed loss of anterior horn cells in the spinal cord concomitant with a reduced level of microglial activation at a late symptomatic stage. Further, the post-onset administration of L-745,870 to the SOD1H46R transgenic mice remarkably slowed the disease progression and extended their life spans. Taken together, our findings in a rodent model of ALS may have implication that L-745,870 is a possible novel therapeutic means to the treatment of ALS. 相似文献
49.
Yoshiyuki Hosokai MS Yoshiyuki Nishio MD PhD Kazumi Hirayama MD PhD Atsushi Takeda MD PhD Toshiyuki Ishioka MS Yoichi Sawada MS Kyoko Suzuki MD PhD Yasuto Itoyama MD PhD Shoki Takahashi MD PhD Hiroshi Fukuda MD PhD Etsuro Mori MD PhD 《Movement disorders》2009,24(6):854-862
There is no consensus with regard to the clinical and neuroimaging characteristics of prodromal dementia in Parkinson's disease (PD). To delineate functional neuroimaging features of PD with mild cognitive impairment (PDMCI) and with no cognitive impairment (PDNC), we compared regional cerebral glucose metabolism (CMRglc) amongst 13 patients with PDMCI, 27 with PDNC, and 13 healthy controls. The PDNC patients had limited areas of hypometabolism in the frontal and occipital cortices. In the PDMCI patients, there were extensive areas of hypometabolism in the posterior cortical regions, including the temporo‐parieto‐occipital junction, medial parietal, and inferior temporal cortices. The present results suggest that posterior cortical dysfunction is the primary neuroimaging feature of PD patients at risk for dementia. © 2009 Movement Disorder Society 相似文献
50.
Sumiya Ishigami Shoji Natsugoe Akihiro Nakajo Masataka Matsumoto Yoshikazu Uenosono Takaaki Arigami Tetsuro Setoyama Hideo Arima Yasuto Uchikado Yoshiaki Kita Ken Sasaki Takashi Aikou 《Journal of gastrointestinal surgery》2008,12(8):1370-1375
Background and aim We investigated the clinical benefits of salvage gastrectomy for stage IV gastric cancer patients whose distant lesions showed
complete response after chemotherapy.
Methods We enrolled 18 stage IV gastric cancer patients whose distant metastases had disappeared or were controlled by a combination
of biweekly paclitaxel (PTX) and S-1. After chemotherapy, these patients received gastrectomy with lymph node dissection.
The postoperative outcome was analyzed with respect to both the histological effects of chemotherapy and tumor behavior.
Results Of the 18 patients, 8 had distant lymph node metastases, 9 had peritoneal dissemination, and five had multiple liver metastases
prior to chemotherapy. Fourteen patients received curative surgery (R0). No severe postoperative complications were encountered.
Pathological evaluation revealed grade 3 and grade 2 tumor regression in the primary lesion in one and five patients, respectively,
and grade 3 and grade 2 tumor regression in the lymph nodes in one and six patients, respectively. Univariate analysis of
the patients’ prognosis identified R number, gross tumor type, histological grade of tumor regression, and gender as significant
factors. Multivariate analysis showed that only the R number was an independent prognostic factor.
Conclusion R0 salvage gastrectomy following a combination of biweekly PTX and S-1 may have significant clinical efficacy for advanced
gastric cancer patients. 相似文献